This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga_article·Oct 2, 2026 at 12:24 PMAVLN+2.59%ELVN+1.64%
Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levelsPUBT·Sep 21, 2026 at 04:11 PMAVLN+2.59%
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety ProfileUnusual Whales·Sep 21, 2026 at 01:02 PMAVLN+2.59%
Avalyn Pharma (NASDAQ:AVLN) Cut to "Sell" at Wall Street ZenMarket Beat·Sep 20, 2026 at 05:12 AMAVLN+2.59%
Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statementPUBT·Sep 17, 2026 at 08:06 PMAVLN+2.59%
Avalyn Pharma names former FDA leader Robert J. Meyer to boardPUBT·Sep 16, 2026 at 08:01 PMAVLN+2.59%
Avalyn Pharma (NASDAQ:AVLN) Trading Up 6.8% - Time to Buy?Market Beat·Sep 14, 2026 at 05:40 PMAVLN+2.59%
Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLNMarket Beat·Sep 3, 2026 at 08:24 AMAVLN+2.59%
Avalyn Pharma advances inhaled pirfenidone AP01 in Phase 2b MIST trial for progressive pulmonary fibrosisPUBT·Aug 24, 2026 at 08:01 PMAVLN+2.59%
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 | AVLN Stock NewsStockTitan·Aug 24, 2026 at 12:01 PMAVLN+2.59%
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected EarningsMarket Beat·Aug 13, 2026 at 05:20 AMAVLN+2.59%
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.benzinga_article·Aug 12, 2026 at 02:11 PMAVLN+2.59%
